Treatment with Aduhelm (aducanumab) showed a significant correlation with lower blood levels of p-tau181, a disease biomarker, and lesser cognitive and functional decline in Alzheimer’s patients, according to a recent data analysis of two Phase 3 clinical trials. The data, analyzed from around 7,000 blood samples collected from more than 1,800 patients who participated in the EMERGE…
AC Immune has announced it will extend its partnership with researchers at the University of Pennsylvania to further study the mechanisms underlying disease-causing changes in the transactive response DNA binding protein 43 kDa (TDP-43). Specifically, company researchers and those with the university’s Center for Neurodegenerative Disease Research at the Perelman School of Medicine are looking into what causes TDP-43…
The MassAITC project was recently launched to focus on using artificial intelligence (AI) to improve in-home care for older adults and others with Alzheimer’s disease, with the help of a five-year, $20-million grant from the National Institute on Aging, a part of the National Institutes of Health. MassAITC, which stands for Massachusetts AI and Technology…
The optimal dosing of tasquinimod, Active Biotech’s experimental oral therapy for adults with relapsed or refractory multiple myeloma, has been determined in a Phase 1b/2a clinical trial. Now, that dose and schedule will be tested, along with the standard oral combination treatment, in the trial’s second phase, the company said in a press release. “We…
The first patient has been recruited, in Finland, for Alzinova AB’s Phase 1b clinical trial testing its ALZ-101 vaccine for Alzheimer’s disease, the company announced. Alzinova AB, a Swedish biopharma company, is working to develop treatments for Alzheimer’s that specifically target amyloid-beta oligomers — chains of several single units (monomers) of the protein. The toxic…
A biological framework called the “microcompetition model” may explain why people infected with herpes simplex 1 (HSV1) are at increased risk of developing Alzheimer’s disease. “These dynamics explain the observed connection reported in many studies between the virus and Alzheimer’s disease, and provide a framework for further investigations,” researchers wrote. This idea was outlined in…
It took seven years from the time she started showing symptoms for Sophia Rodriguez’s mother to receive a confirmed diagnosis of Alzheimer’s disease. After her death 14 years later, Rodriguez can’t help but wonder how things might have been different had her mother received an earlier diagnosis. Early diagnosis has myriad benefits for those living…
After promising early results, a sub-study of the DREAMM-5 platform trial is moving forward to its next phase to test a combination of Blenrep (belantamab mafodotin) with nirogacestat in adults with relapsed or refractory multiple myeloma. In addition, two sub-studies will be added to the trial (NCT04126200), sponsored by Blenrep developer GlaxoSmithKline (GSK), to evaluate…
Detailed molecular signatures in three mouse models of Alzheimer’s disease at different disease stages allowed for identification of four approved medicines that may be potential Alzheimer’s treatments, a study revealed. The four medications that demonstrated efficiency are now used to treat hypertension (high blood pressure) and inflammation in humans. The study, “Identification and drug-induced reversion…
The U.S. Food and Drug Administration (FDA) is expected to decide by the end of February whether or not to approve ciltacabtagene autoleucel, known as cilta-cel, an investigational CAR T-cell therapy for the treatment of relapsed or refractory multiple myeloma. The FDA extended its expected decision date to allow sufficient time to review information about…
